Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5‐year survival rate below 13% and limited treatment options due to rapid metastasis and pronounced chemoresistance. Gemcitabine (Gem) remains a first‐line chemotherapy agent; however, its clinical efficacy is hindered...

全面介绍

书目详细资料

Principais autores:	Tamanna Binte Huq, Sudip Kumar Dam, Doaha Awad, Punnya Anil Kumar Jeeja, Farzana Ferdous, Juan L. Vivero‐Escoto
格式:	Artigo
语言:	Inglês
出版:	Wiley-VCH 2026-07-01
丛编:	Advanced NanoBiomed Research
主题:	combination therapy controlled release gemcitabine resistance mesoporous silica nanoparticles pancreatic cancer
在线阅读:	https://doi.org/10.1002/anbr.202500255
标签:	添加标签 没有标签, 成为第一个标记此记录!